---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-134389"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T13:01:22.328317+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Natera Q3 revenue $158.1M (+61% YoY), net loss $151.3M; raises FY2021 revenue guidance

## Summary
- Revenue $158.1M (+61.1% YoY); product revenue $150.7M (+61.5%); tests processed 407,300 (+55.4%).
- Net loss $151.3M (EPS -$1.63) vs loss $58.3M (-$0.72) in Q3 2020; operating loss $150.2M.
- Raises 2021 revenue guidance to $615-625M from prior; expects gross margin 49-52%; SG&A $500-520M; R&D $240-260M.
- Cash $1.0B; total debt $330.1M ($287.5M convertible notes principal; $50M credit line).
- Launched Prospera Kidney/Heart/Lung; exclusive license from Aarhus University for colorectal cancer screening biobank.

## SEC filing metadata
- accession: 0001104659-21-134389
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465921134389/0001104659-21-134389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465921134389/tm2131935d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-134389
- JSON: https://secwatch.observer/filing/0001104659-21-134389.json
- Plain text: https://secwatch.observer/filing/0001104659-21-134389.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.